Evotec and Immuneering Collaborates to Develop Novel Candidates for Rare Hereditary Metabolic Diseases

 Shots:

• The collaboration is a focus of combining Evotec’s stem cell (“iPSC”) platform with Immuneering’s Artificial Intelligence drug discovery platform for development of therapies
• Additionally, Immuneering’s AI platform fluency will assist in analyzing public and proprietary data, for identification of novel candidates
• AI platform is a drug discovery based technology used to discover & develop single and multi-targeted drugs with molecular-level data

Click here to read full press release/ article | Ref: Evotec | Image: The Pharma Letter